Nicorette Invisi Transdermal Patch

Nicorette Invisi Transdermal Patch Drug Interactions

nicotine

Manufacturer:

Johnson & Johnson

Distributor:

Zuellig Pharma
Full Prescribing Info
Drug Interactions
Smoking (but not nicotine) is associated with increased activity of CYP1A2. After giving up smoking, clearance of certain medications which are metabolized via CYP1A2 may be reduced. This may lead to increased plasma levels of certain medications. The increase may be of clinical significance for products with narrow therapeutic windows e.g. theophylline, tacrine, clozapine or ropinirole.
Plasma level of other medications which are in part metabolized via CYP1A2 e.g. imipramine, olanzapine, clomipramine and fluvoxamine, might also rise after stop smoking. There are no data supporting this however, and the possible clinical significance of this effect on these medications is unknown.
Limited data indicates that the metabolism of flecainide and pentazocine might also be capable of being induced by smoking.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in